下咽癌合并多中心型Castleman病1例

孙乐; 祝威; 翟佳琦; 于婷婷

doi:10.13201/j.issn.1001-1781.2018.14.018

下咽癌合并多中心型Castleman病1例

- 吉林大学白求恩第一医院耳鼻喉科(长春, 130000)
基金项目:
吉林省科技发展计划基金（No：20160101051JC）

详细信息

通讯作者: 于婷婷,E-mail:yutingting198310@163.com

中图分类号: R739.6

收稿日期: 2017-08-06

A case report of hypopharyngeal carcinoma with multicentric Castleman disease

More Information

Corresponding author: YU Tingting, E-mail: yutingting198310@163.com

Received Date: 06 August 2017

摘要

- 下咽癌 /
- Castleman病
Abstract: Hypopharyngeal carcinoma is the worst malignant tumor in the head and neck squamous cell carcinoma, which has the worst prognosis. As the hypopharynx has a rich lymphatic network, cervical lymph node metastasis is very easy to occur. Castleman disease is vascular follicular lymphnode hyperplasia, a rare chronic lymphoproliferative disease of unknown cause. In the diagnosis of Castleman disease, attention should be paid to the differential diagnosis of head and neck malignant tumors.
- hypopharyngeal carcinoma /
- Castleman disease

HTML全文

参考文献(24)

[1]	COOPER J S, PORTER K, MALLIN K, et al.National Cancer Database report on cancer of the head and neck:10-year update[J].Head Neck, 2009, 31:748-758.
[2]	GOURIN C G, TERRIS D J.Carcinoma Of the hypopharynx[J].Surg Oncol Clin N Am, 2004, 13:81-98.
[3]	赵坚强.下咽癌的治疗进展[J].中国医药导报, 2014, 11(13):161-163.
[4]	CASTLEMAN B.Case records of the Massachusetts General Hospital Weekly Clinicopathological Exercises:Case 40011[J].N Engl J Med, 1954, 250:26-30.
[5]	CASTLEMAN B, IVERSON L, MENENDEZ V P.Localized mediastinal lymphnode hyperplasia resembling thymoma[J].Cancer, 1956, 9:822-830.
[6]	VAN RHEE F, STONE K, SZMANIA S, et al.Castleman disease in the 21st century:An update on diagnosis, assessment, and therapy[J].Clin Adv Hematol Oncol, 2010, 8:486-498.
[7]	CHEN Y F, ZHANG W D, SUN C Z, et al.Clinical features and outcomes of head and neck castleman disease[J].J Oral Maxillofac Surg, 2012, 70:2466-2479.
[8]	EATON C, DORER R, ABOULAFIA D M.Human herpesvirus-8infection associated with Kaposi sarcoma, multicentric Castleman's disease, and plasmablastic microlymphoma in a man with AIDS:A case report with review of pathophysiologic processes[J].Pathol Res Int, 2010, 2011:647518.
[9]	MENKE D M, CHADBUM A, CESARMAN E, et al.Analysis of the human herpesvirus 8(HHV-8) genome and HHV-8vIL-6expression in archival cases of Castleman disease at low risk for HIV infection[J].Am J Clin Pathol, 2002, 117:268-275.
[10]	CHEN C H, LIU H C, HUNG T T, et al.Possible roles of Epstein-Barrvirus in Castleman disease[J].J Cardiothorac Surg, 2009, 4:31.
[11]	GOMES H, HUYETT P, LAVER N, et al.A unique presentation of Epstein-Barr virus-associated Castleman's disease[J].Am J Otolaryngol, 2013, 34:262-264.
[12]	GERMAINE L M, NEWHOUSE J H.Castleman's disease[J].Clin Imaging, 2003, 27:431-434.
[13]	WANG R, NA J, BIN H, et al.Characteristic calcification of localized Castleman's disease:CT and histopathologic appearance[J].Chin J Radiol, 2002, 36:355-357.
[14]	YOON D Y, HWANG H S, CHANG S K, et al.CT, MR, US, 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck[J].Eur Radiol, 2009, 19:634-642.
[15]	CRONIN D M, WARNKE R A.Castleman disease:An update on classification and the spectrum of associated lesions[J].Adv Anat Pathol, 2009, 16:236-246.
[16]	IYONAGA K, ICHIKADO K, MURANAKA H, et al.Multicentric Castleman's disease manifesting in the lung:clinical, radiographic, and pathologic findings and successful treatment with corticosteroid and cyclophosphamide[J].Intern Med, 2003, 42:182-186.
[17]	BANDERA B, AINSWORTH C, SHIKLE J, et al.Treatment of unicentric Castleman disease with neoadjuvant rituximab[J].Chest, 2010, 138:1239-1241.
[18]	NICOLI P, FAMILIARI U, BOSA M, et al.HHV8-positive, HIV-negative multicentric Castleman's disease:Early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma[J].Int J Hematol, 2009, 90:392-396.
[19]	HOFFMANN C, SCHMID H, MÜLLER M, et al.Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease[J].Blood, 2011, 118:3499-3503.
[20]	HIGUCHI T, NAKANISHI T, TAKADA K, et al.A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6receptor antibody, tocilizumab[J].J Korean Med Sci, 2010, 25:1364-1267.
[21]	OKSENHENDLER E, BOULANGER E, GALICIER L, et al.High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease[J].Blood, 2002, 99:2331-2336.
[22]	LEFEBVRE J L, POINTREAU Y, ROLLAND F, et al.Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation:the TREMPLIN randomized phaseⅡstudy[J].J Clin Oncol, 2013, 31:853-859.
[23]	KUO P, CHEN M M, DECKER R H, et al.Hypopharyngeal cancer incidence, treatment, and survival:temporal trends in the United States[J].Laryngoscope, 2014, 124:2064-2069.
[24]	BAEK H J, KOOK H, HAN D K, et al.Unicentric castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent[J].Pediatr Hematol Oncol, 2012, 34:e206-e208.